IMvigor211, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of atezolizumab versus chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen

NCT02302807    




Studied treatment atezolizumab
Control treatment chemotherapy



Patients patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen
Size932



Blindness open label Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint overall survival Design Parallel groups



EndpointX1N1X0N0TE95% CI0,22,01,0

negative (press realease)




Press release

ClinicalTrial.gov record NCT02302807



Registering number NCT02302807 (see trial on clinicaltrials.gov)
Code Name

 

Appears in following systematic reviews: